2-(4-肼基苯基)乙酸乙酯 | 367255-29-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(4-肼基苯基)乙酸乙酯
• 英文名称: 1.4-(Carboethoxymethyl)phenylhydrazine
• 英文别名: ethyl-p-hydrazinophenylacetate；4-hydrazinophenylacetic acid ethyl ester；4-ethoxycarbonylmethylphenylhydrazine；Ethyl 2-(4-hydrazinylphenyl)acetate
• CAS: 367255-29-6
• 化学式: C₁₀H₁₄N₂O₂
• mdl: MFCD12197646
• 分子量: 194.233
• InChiKey: QNUMWVBHRJVVGE-UHFFFAOYSA-N

物化性质

• 沸点：
  332.1±25.0 °C(Predicted)
• 密度：
  1.174±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(4-肼基苯基)乙酸乙酯 在 氢氧化钾 、 sodium tetrahydroborate 、 硫酸 、 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 三乙胺 、 N,N-二异丙基乙胺 、 硫酸二甲酯 作用下， 以 四氢呋喃 、 甲醇 、 氘代氯仿 、 二氯甲烷 为溶剂， 生成 {2-[5-diethylcarbamoylmethyl-2-(3,5-dimethylphenyl)-1H-indol-3-yl]ethyl}-[4-(4-methanesulfonylaminophenyl)butyl]-carbamic acid benzyl ester
  参考文献：
  名称：

  Substituted Indole-5-carboxamides and -acetamides as Potent Nonpeptide GnRH Receptor Antagonists

  摘要：

  The 2-aryltryptamine class of GnRH receptor antagonists has been modified to incorporate carboxamide and acetamide substituents at the indole 5-position. With either a phenol or methanesulfonamide terminus on the N-aralkyl side chain, potent binding affinity to the GnRH receptor was achieved. A functional assay for GnRH antagonism was even more sensitive to structural modification and revealed a strong preference for branched tertiary amides. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00274-8
• 作为产物：
  描述：

  4-氨基苯乙酸乙酯 在 盐酸 、 sodium nitrite 、 tin(ll) chloride 作用下， 生成 2-(4-肼基苯基)乙酸乙酯
  参考文献：
  名称：

  Substituted Indole-5-carboxamides and -acetamides as Potent Nonpeptide GnRH Receptor Antagonists

  摘要：

  The 2-aryltryptamine class of GnRH receptor antagonists has been modified to incorporate carboxamide and acetamide substituents at the indole 5-position. With either a phenol or methanesulfonamide terminus on the N-aralkyl side chain, potent binding affinity to the GnRH receptor was achieved. A functional assay for GnRH antagonism was even more sensitive to structural modification and revealed a strong preference for branched tertiary amides. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00274-8

文献信息

• [EN] PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS<br/>[FR] PYRIMIDYL CYCLOPENTANES EN TANT QU'INHIBITEURS DE PROTÉINE KINASE AKT
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2009089454A1

  公开（公告）日：2009-07-16

  The present invention provides compounds of Formula (I) including tautomers, resolved enantiomers, resolved diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as Akt protein kinase inhibitors and for the treatment of Akt-mediated diseases, for example, hyperproliferative diseases such as cancer.

  本发明提供了式（I）的化合物，包括互变异构体、已分离的对映体、已分离的非对映异构体、溶剂合物、代谢物、盐以及其药学上可接受的前药。本发明还提供了使用这些化合物作为Akt蛋白激酶抑制剂以及用于治疗Akt介导的疾病，例如，高增殖性疾病如癌症的方法。
• Enzyme modulators and treatments
  申请人：Flynn L. Daniel

  公开号：US20070078121A1

  公开（公告）日：2007-04-05

  Novel compounds and methods of using those compounds for the treatment of inflammatory conditions, immunological disorders, hyperproliferative diseases, cancer, and diseases characterized by hyper-vascularization are provided. In a preferred embodiment, modulation of the activation state of kinases, including p38 kinase protein, abl kinase protein, bcr-abl kinase protein, braf kinase protein, VEGFR kinase protein, or PDGFR kinase protein, comprises the step of contacting said kinase protein with the novel compounds.

  提供了新型化合物及其使用方法，用于治疗炎症性疾病、免疫性疾病、过度增生性疾病、癌症以及以高血管化为特征的疾病。在一种优选实施方式中，调节激酶的激活状态，包括p38激酶蛋白、abl激酶蛋白、bcr-abl激酶蛋白、braf激酶蛋白、VEGFR激酶蛋白或PDGFR激酶蛋白，包括将该激酶蛋白与新型化合物接触的步骤。
• Substituted Pyrazolyl Urea Derivatives Useful in the Treatment of Cancer
  申请人：Lee Wendy

  公开号：US20080214545A1

  公开（公告）日：2008-09-04

  The present invention relates to compounds of formula (I), pharmaceutical compositions which contain them and methods for treating cancer using compounds of formula (I).

  本发明涉及式(I)的化合物，包含它们的药物组合物以及使用式(I)的化合物治疗癌症的方法。
• ENZYME MODULATORS AND TREATMENTS
  申请人：Flynn L. Daniel

  公开号：US20080113967A1

  公开（公告）日：2008-05-15

  Novel compounds and methods of using those compounds for the treatment of inflammatory conditions, hyperproliferative diseases, cancer, and diseases characterized by hyper-vascularization are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein, abl kinase protein, ber-abl kinase protein, braf kinase protein, VEGFR kinase protein, or PDGFR kinase protein comprises the step of contacting said kinase protein with the novel compounds.

  本发明提供了新的化合物及其使用方法，用于治疗炎症状况、过度增殖性疾病、癌症和以高血管化为特征的疾病。在优选实施例中，调节p38激酶蛋白、abl激酶蛋白、ber-abl激酶蛋白、braf激酶蛋白、VEGFR激酶蛋白或PDGFR激酶蛋白的激活状态，包括将该激酶蛋白与新的化合物接触的步骤。
• PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS
  申请人：Banka Anna

  公开号：US20110053959A1

  公开（公告）日：2011-03-03

  The present invention provides compounds of Formula (I) including tautomers, resolved enantiomers, resolved diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as Akt protein kinase inhibitors and for the treatment of Akt-mediated diseases, for example, hyperproliferative diseases such as cancer.

  本发明提供了公式（I）的化合物，包括互变异构体、分离的对映体、分离的二对映异构体、溶剂化物、代谢物、盐和其药学上可接受的前药。还提供了使用本发明化合物作为Akt蛋白激酶抑制剂和用于治疗Akt介导的疾病（例如，癌症等增殖性疾病）的方法。